Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.
|
|
- Garry Berry
- 8 years ago
- Views:
Transcription
1 PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes. Trial Acronym ISODIA URL of the trial [---]* Brief Summary in Lay Language The study investigates the effect of replacing 50g sucrose per day by isomaltulose in sweet food and beverages on metabolic control in subjects with type 2 diabetes. The study tests the hypothesis, whether isomaltulose vs. sucrose results in improved glycemic control assessed as HbA1c after 12 weeks. Brief Summary in Scientific Language The study investigates the effect of replacing 50g sucrose per day by the low-glycemic sugar isomaltulose in sweet food and beverages on metabolic control in subjects with type 2 diabetes under free-living conditions. Primary endpoint of the study is HbA1c at 12 weeks after study start. The aim of study is to test the hypothesis whether replacing 50 g/d sucrose by isomaltulose in sweet foods and beverages over a period of 12 weeks would result in improved glycemic control assessed as HbA1c as and metabolic parameters associated with cardiovascular risk in individuals with type 2 diabetes. Organizational Data DRKS-ID: DRKS Date of Registration in Partner Registry or other Primary Registry: [---]* Investigator Sponsored/Initiated Trial (IST/IIT): yes Ethics Approval/Approval of the Ethics Committee: Approved (leading) Ethics Committee Nr.: Projekt-Nr.: 1669/06, Ethik-Kommission der Fakultät für Medizin der Technischen Universität München Page 1 of 6
2 DRKS-ID: DRKS Date of Registration in Partner Registry or other Primary Registry: [---]* Investigator Sponsored/Initiated Trial (IST/IIT): yes Ethics Approval/Approval of the Ethics Committee: Approved (leading) Ethics Committee Nr.: Projekt-Nr.: 1669/06, Ethik-Kommission der Fakultät für Medizin der Technischen Universität München Secondary IDs Health condition or Problem studied Free text: Type 2 Diabetes ICD10: E Non-insulin-dependent diabetes mellitus; Without complications Interventions/Observational Groups Arm 1: 50 g per day sucrose by sweet foods and beverages over a period of 12 weeks Arm 2: 50 g per day isomaltulose by sweet foods and beverages over a period of 12 weeks Characteristics Study Type: Interventional Study Type Non-Interventional: [---]* Allocation: Randomized controlled trial Blinding: Double or multiple blind Who is blinded: [---]* Control: Active control Purpose: Other Assignment: Parallel Phase: N/A Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): N/A Page 2 of 6
3 Primary Outcome HbA1c after 12 weeks of treatment Secondary Outcome - Parameters of glucose metabolism (fasting glucose, insulin,c-peptide, fructosamine, HOMA-IR): baseline, after 6 and after 12 weeks (by an external laboratory according to standard procedures) - blood lipids (cholesterol, triglycerides): baseline, after 6 and after 12 weeks (by an external laboratory according to standard procedures) - Adipokines (leptin, adiponectin) baseline, after 6 and after 12 weeks (by ELISA) - nutritional intake over the course of the study (baseline, week 4, 6 and 10 by 3 day dietary records) - tolerance/ gastrointestinal parameters: clinical routine parameters (blood count, coagulation, liver enzymes) at baseline, after 6 and after 12 weeks; gastrointestinal parameters and stool characteristics by questionnaires fortnightly over the course of the study - self monitored blood glucose profiles fortnightly over the course of the study (before and 90 min after the three main meals) by a blood glucose meter handed out to the patients Countries of recruitment DE Locations of Recruitment University Medical Center Klinikum rechts der Isar, Technische Universität München, Else Kröner-Fresenius Zentrum für Ernährungsmedizin, München University Medical Center Medizinische Klinik und Poliklinik II, Schwerpunkt Gastroenterologie, Würzburg Recruitment Planned/Actual: Actual (Anticipated or Actual) Date of First Enrollment: 2007/03/01 Target Sample Size: 110 Monocenter/Multicenter trial: Multicenter trial National/International: National Inclusion Criteria Gender: Both, male and female Page 3 of 6
4 Gender: Both, male and female Minimum Age: 18 Years Maximum Age: no maximum age Additional Inclusion Criteria written informed consent, sex: female or male, age >18 years, BMI kg/m2, confirmed type 2 diabetes mellitus, diabetes treatment with diet alone or oral antidiabetic agents (insulin secretagogues, metformin, insulin sensitizers, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors) without changes in the therapy regimen for at least three months prior to study start, HbA1c % assessed in the screening visit, usual daily intake of g sucrose or sucrose equivalent from sweetened foods or beverages assessed by 3-d dietary records before study start, willingness to regular consumption of test products, preference for sweet food in habitual diet, willingness to restrict intake of sweet foods other than the test products, 3 meals in the habitual diet Exclusion criteria treatment with insulin, presence or history of severe chronic disease, pregnancy and lactation, glucocorticoid therapy, abnormal dietary habits and dislike of sweetened foods. Addresses Primary Sponsor Else Kröner-Fresenius-Zentrum für Ernährungsmedizin Klinikum rechts der Isar Uptown München Campus D Mr. Prof. Dr. med Hans Hauner Georg-Brauchle-Ring 69/ München Telephone: Fax: hans.hauner at tum.de Page 4 of 6
5 Contact for Scientific Queries Else Kröner-Fresenius-Zentrum für Ernährungsmedizin Klinikum rechts der Isar Uptown München Campus D Mr. Prof. Dr. med. Hans Hauner Georg-Brauchle Ring 60/ München Telephone: Fax: hans.hauner at tum.de Contact for Public Queries Else Kröner-Fresenius-Zentrum für Ernährungsmedizin Klinikum rechts der Isar Uptown München Campus D Ms. M. Sc. Stefanie Brunner Georg-Brauchle-Ring 60/ München Telephone: Fax: stefanie.brunner at wzw.tum.de Sources of Monetary or Material Support Commercial (pharmaceutical industry, medical engineering industry, etc.) SÜDZUCKER AG Mannheim/Ochsenfurt Wormser Straße Obrigheim/Pfalz Telephone: [---]* Fax: [---]* [---]* Status Recruitment Status: Recruiting complete, follow-up complete Study Closing (LPLV): 2008/12/19 Page 5 of 6
6 Trial Publications, Results and other documents * This entry means the parameter is not applicable or has not been set. Page 6 of 6
Feasibility study to evaluate the usability of the newly developed health care management software ecare*seniors in primary care practices.
Trial Description Title Patient-centered health care management in primary care: feasibility study evaluating the usability of the computer-based information system ecare*seniors for the individual health
More informationTrial Description. DRKS-ID: DRKS00006862 Date of Registration in DRKS: 2015/03/06 Date of Registration in Partner Registry: [---]*
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Treatment with new oral anticoagulants in primary care practices Trial Acronym [---]* URL of the trial [---]* Brief
More informationDopaminergic and cholinergic modulation of oculomotor control during saccades
Trial Description Title Dopaminergic and cholinergic modulation of oculomotor control during saccades Trial Acronym URL of the trial Brief Summary in Lay Language In this basic science study we investigate
More informationTrial Description. Organizational Data. Secondary IDs
Trial Description Title A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients
More informationEvaluation of a patient's ressource srengthening psychotherapeutic intervention in treatment of residual depression symptoms
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Euthymic Therapy: a Randomised Controlled Trial Trial Acronym [---]* URL of the trial [---]* Brief Summary in Lay Language
More informationWork-related diseases of occupational therapists - pilot study for creating an "occupational therapist-cohort" in Germany
Trial Description Title Work-related diseases of occupational therapists - pilot study for creating an "occupational therapist-cohort" in Trial Acronym ERGO-Study URL of the trial [---]* Brief Summary
More informationRaman spectroscopy: Setup of an experimental system for analysis of urinary stone composition
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title Raman spectroscopy: Setup of an experimental system for analysis of urinary stone composition Trial Acronym Ramalith
More informationWAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue
PLEASE NOTE: This trial has been registered retrospectively. Trial Description Title WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue Trial Acronym
More informationTrial Description. DRKS-ID: DRKS00006819 Date of Registration in DRKS: 2014/10/31 Date of Registration in Partner Registry: [---]* Title
Trial Description Title SCHILD - protective intervention for longtime course in depression Trial Acronym SCHILD URL of the trial [---]* Brief Summary in Lay Language Even if depression is treated appropriate
More informationIn this observational study, the effect of dabigatran and rivaroxaban on platelets will be evaluated.
Trial Description Title Effect of dabigatran and rivaroxaban on Platelets Trial Acronym BIG-ROX-P URL of the trial [---]* Brief Summary in Lay Language In this observational study, the effect of dabigatran
More informationChanges in liver volume as determined by MRI scans after two weeks of a low energy diet (t0: before start of the diet; t1: after two weeks of diet)
Trial Description Title Influence of different preoperative low energy diets on changes in liver volume, liver fat content, visceral fat and body composition as well as liver and adipose tissue mrna expression
More informationProspective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL
Trial Description Title Prospective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL Trial Acronym SUPRATOL URL of the trial [---]*
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationI. Research Proposal. 1. Background
Sample CFDR Research Proposal I. Research Proposal 1. Background Diabetes has been described as the the perfect epidemic afflicting an estimated 104 million people worldwide (1). By 2010, this figure is
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationMetabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement
CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationKansas Behavioral Health Risk Bulletin
Kansas Behavioral Health Risk Bulletin Kansas Department of Health and Environment November 7, 1995 Bureau of Chronic Disease and Health Promotion Vol. 1 No. 12 Diabetes Mellitus in Kansas Diabetes mellitus
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationBaskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationGlycemic Control of Type 2 Diabetes Mellitus
Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Glycemic Control of Type 2 Diabetes Mellitus Majeda Fikree* Baderuldeen Hanafi** Zahra Ali Hussain** Emad M Masuadi*** Objective: To determine the
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationUsing the Concept of Being Safe as a Positive Motivator In Diabetes Education
Inova Health System Using the Concept of Being Safe as a Positive Motivator In Diabetes Education Ann Carnes MN RN CDE Sally Guise RD CDE AADE Annual Meeting August 6, 2009 Why Safety? 67% of Americans
More informationPoorly controlled diabetes mellitus the way forward
Poorly controlled diabetes mellitus the way forward Presentation at HA Convention 2008 6 May, 2008 Dr. M K Cheung Associate Consultant Department of Family Medicine Community Care Division New Territories
More informationInsulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial
Nutrition, Physical Activity and Metabolism Conference 2011 Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial Qibin
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationBIAsp30 A 1 chieve Tehran 31 July 2015
BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of
More informationTHE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS
THE IMPACT OF USING BLOOD SUGAR HOME MONITORING DEVICE TO CONTROL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS Alshammari S., *Al-Jameel N., Al-Johani H, Al-Qahtani A., Al-Hakbani A., Khan A. and Alfaraj S.
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationStatistics of Type 2 Diabetes
Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often
More informationPLEASE NOTE: This study has been imported from ClinicalTrials.gov without additional data checks.
PLEASE NOTE: This study has been imported from ClinicalTrials.gov without additional data checks. Trial Description Title A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationTraditional View of Diabetes. Are children with type 1 diabetes obese: What can we do? 8/9/2012. Change in Traditional View of Diabetes
Are children with type 1 diabetes obese: What can we do? Traditional View of Diabetes Type 1 Diabetes ( T1DM) Onset Juvenile Lean Type 2 Diabetes ( T2DM) Onset Adult Obese QI Project Indrajit Majumdar
More informationLearning Objectives. ADA Diet vs. Medical Nutrition Therapy. In Diabetes, Food IS Medicine: Current Trends In Diabetes Nutrition Management
In Diabetes, Food IS Medicine: Current Trends In Diabetes Nutrition Management Laurel Najarian RD, CDE, M.ED Learning Objectives 1. Discuss the rationale and importance for the use of carbohydrate counting
More informationAccountable Care Project EMR Reporting Guide January 6, 2014
Accountable Care Project EMR Reporting Guide January 6, 2014 Web Reporting System The system can be accessed at http://www.nhaccountablecare.org. You will need the ID and password assigned to you by NHIHPP
More informationDiabetes Self Management Training Insulin Pump Follow Up
701 East Marshall Street, West Chester, PA 19380 www.chestercountyhospital.org 610.431.5000 Diabetes Self Management Training Insulin Pump Follow Up Patient Name: Visit Date: Time: To prepare for your
More informationThe Polyphenol Study. Effect of Dietary Polyphenols on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome
The Polyphenol Study Effect of Dietary Polyphenols on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome Principal Investigator: Michael Lefevre, PhD What are Polyphenols? * Polyphenols
More informationThe first endoscopically-delivered device therapy for obese patients with type 2 diabetes
DIABETES WEIGHT ENDOBARRIER THERAPY The first endoscopically-delivered device therapy for obese patients with type 2 diabetes Restore the metabolic health of your patients with EndoBarrier Therapy. Dual
More informationUnderstanding Diseases and Treatments with Canadian Real-world Evidence
Understanding Diseases and Treatments with Canadian Real-world Evidence Real-World Evidence for Successful Market Access WHITEPAPER REAL-WORLD EVIDENCE Generating real-world evidence requires the right
More informationCarbohydrate Counting. Who chooses what you eat every day? Setting The Stage. Pre-Test. Pre-Test. Eating for Diabetes Made Easier
Carbohydrate Counting Eating for Diabetes Made Easier Kris Williams, MS RD Department of Health Education Kaiser Permanente, Kern County Setting The Stage Who chooses what you eat every day? Pre-Test.
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationWhich drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationSummary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06
CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationBritish Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes
British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes Introduction Self-monitoring of blood glucose (SMBG) is in widespread use among
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationSection 5: Type 2 Diabetes
SECTION OVERVIEW Definition and Symptoms Blood Glucose Monitoring Healthy Eating Physical Activity Oral Medication Insulin Sharps Disposal Definition and Symptoms Type 2 diabetes is occurring more frequently
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationDiabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
More informationA prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):33-37 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationWHO STEPwise approach to chronic disease risk factor surveillance (STEPS)
WHO STEPwise approach to chronic disease risk factor surveillance (STEPS) Promotion of Fruits and Vegetables for Health African Regional Workshop for Anglophone Countries Mount Meru Hotel, Arusha, Tanzania
More informationSedentarity and Exercise in the Canadian Population. Angelo Tremblay Division of kinesiology
Sedentarity and Exercise in the Canadian Population Angelo Tremblay Division of kinesiology Disclosure of Potential Conflicts of Interest Évolution de la pratique d activité physique des adultes canadiens
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationIntracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationPATHWAYS TO TYPE 2 DIABETES. Vera Tsenkova, PhD Assistant Scientist Institute on Aging University of Wisconsin-Madison
PATHWAYS TO TYPE 2 DIABETES Vera Tsenkova, PhD Assistant Scientist Institute on Aging University of Wisconsin-Madison Overview Diabetes 101 How does diabetes work Types of diabetes Diabetes in numbers
More informationA Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis
A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information
More informationDEVELOPING WHEY-BASED INNOVATIVE BIOACTIVE INGREDIENTS. Éric Simard, Ph.D. Vice-President, Operations BiolActis, Canada
DEVELOPING WHEY-BASED INNOVATIVE BIOACTIVE INGREDIENTS Éric Simard, Ph.D. Vice-President, Operations BiolActis, Canada Modus Operandi BiolActis commercializes innovative and clinically proven Whey-Based
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationA STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS
RESEARCH ARTICLE A STUDY OF MAGNESIUM SUPPLEMENTATION ON GLYCEMIC CONTROL IN PATIENTS OF TYPE-2 DIABETES MELLITUS Yogendra Raj Singh 1, Shilpi Verma 2, Dushyant Agrawal 3,*, Brijendra Singh 4, Ashutosh
More informationMEDICATION THERAPY ADHERENCE CLINIC : DIABETES
MEDICATION THERAPY ADHERENCE CLINIC : DIABETES PHARMACEUTICAL SERVICES DIVISION MINISTRY OF HEALTH MALAYSIA First Edition, 2010 Pharmaceutical Services Division Ministry of Health, Malaysia ALL RIGHT RESERVED
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationInpatient Treatment of Diabetes
Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient
More informationFreiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.
Freiburg Study The Freiburg Study was conducted with 48 healthy human subjects of various ages. None of the test subjects had been diagnosed with any disease prior to the study. None were taking any type
More informationDouble Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention.
Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention. Professor Paolo Pozzilli University Campus Bio-Medico, Rome Institute of Cell & Molecular Science, Queen Mary, University of
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationThe CSIRO Total Wellbeing Diet -from lab bench to kitchen bench. Manny Noakes CSIRO Food and Nutritional Sciences
The CSIRO Total Wellbeing Diet -from lab bench to kitchen bench Manny Noakes CSIRO Food and Nutritional Sciences Any approach to weight loss? CSIRO Lower Carbohydrate Higher Protein Pattern Extensively
More informationSharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com
SAMPLE CRA CV Sharon H. Johnson, BS, MS 123 Main Street Capital City, VA 00000 Phone: 434-555-1234 Email: shjohnson@email.com Education: Masters of Science, Healthcare Administration, Capital City University,
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More informationFacts about Diabetes in Massachusetts
Facts about Diabetes in Massachusetts Diabetes is a disease in which the body does not produce or properly use insulin (a hormone used to convert sugar, starches, and other food into the energy needed
More informationDiabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.
Diabetes Brief What is Diabetes? Diabetes mellitus is a disease of abnormal carbohydrate metabolism in which the level of blood glucose, or blood sugar, is above normal. The disease occurs when the body
More informationPersonalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach
Personalized Therapy Algorithms for Type 2 Diabetes: A Phenotypization-based Approach Riccardo Candido on behalf of the Personalized Therapy AMD Study Group Diabetes Canter A.S.S. 1 Triestina, Italy BACKGROUND
More informationMarkham Stouffville Hospital
Markham Stouffville Hospital Adult Diabetes Education Frequently Asked Questions What is diabetes? Diabetes is a disease in which blood glucose levels are above normal. Most of the food we eat is turned
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationMEDICAL POLICY POLICY TITLE DIABETIC SELF-MANAGEMENT TRAINING PROGRAM POLICY NUMBER MP- 2.076
Original Issue Date (Created): July 1, 2005 Most Recent Review Date (Revised): Effective Date: May 24, 2011 August 31, 2011- RETIRED I. POLICY Initial diabetic self-management training (DSMT) may be considered
More informationPolicy For The Adjustment Of Insulin Dose For Patients With Diabetes By Diabetes Specialist Dietitians And Cystic Fibrosis Dietitians In NHS Grampian
Policy For The Adjustment Of Insulin Dose For Patients With Diabetes By Diabetes Specialist Dietitians And Cystic Fibrosis Dietitians In NHS Grampian Co-ordinators: Advanced Dietitian (Diabetes) Consultation
More informationUpdates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes
dates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO Managing Complicated Diabetes Diabetes is increasingly common Managing diabetes and working as part of a multidisciplinary team is essential
More informationWelcome to Diabetes Education! Why Should I Take Control of My Diabetes?
Welcome to Diabetes Education! Why Should I Take Control of My Diabetes? NEEDS and BENEFITS of SELF-MANAGEMENT You make choices about your life and health Controlling diabetes needs every day decisions
More informationService Skills Australia. Fitness Training Package Consultation. April 2014
Service Skills Australia Fitness Training Package Consultation April 2014 The Dietitians Association of Australia (DAA) is the national association of the dietetic profession with over 5500 members, and
More information